Drug-resistant tuberculosis [2]

Lancet

Volumn 357, Issue 9264, 2001, Pages 1288-1289

  Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; CELL MEMBRANE PERMEABILITY; CHEMOTHERAPY; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0035925911     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04427-5     Document Type: Letter

References (5)

1. MA Espinal SI Kim PG Suarez Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcome in 6 countries JAMA 283 2000 2537 2545
2. CB Inderlied M Salfinger Antimicrobial agents and susceptibility tests: mycobacteria Murray PR Baron EJ Pfaller MA Tenover FC Yolken RH Manual of clinical microbiology 1995 DC: American Society for Microbiology Press Washington 1385 1404
3. T Bodmer G Zürcher P Imboden A Telenti Mutation position and type of substitution in the 3-subunit of the RNA polymerase influence in-vitro activity of rifamycin and rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 35 1995 345 348
4. A Meier P Sander KJ Schaper Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 40 1996 2452 2454
5. B Yang H Koga H Ohno Relationship between antimicrobial activities of rifampicin, ribabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. Antimicrob Chemother 42 1998 621 628